FENTANYL (fentanyl citrate) by Teva is analgesia. First approved in 1993.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
Fentanyl citrate is a potent synthetic opioid agonist approved as an oral troche/lozenge formulation for analgesia. It works by binding to opioid receptors in the central nervous system to provide rapid pain relief. This formulation enables quick-onset pain control suitable for breakthrough pain management.
Product approaching loss of exclusivity with moderate competitive pressure (30%); commercial teams should expect portfolio transition planning and defensive strategies.
analgesia.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade
A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors
A Comparative Study on Three Different Doses of Intrathecal Hyperbaric Prilocaine With Fentanyl for Optimal Dose to be Used in Elderly Patients Undergoing Day Case Lower Abdominal and Urologic Surgeries.
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
Worked on FENTANYL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on fentanyl citrate offers limited career growth given the approaching LOE and zero linked job postings; roles focus on defending market share and managing decline. This is a defensive turnaround opportunity suited for professionals with cost management and legacy product expertise.